# Akebia Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Akebia Therapeutics, Inc.). ## Overview Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications. Its current business is built around treating complications of chronic kidney disease, especially anemia in dialysis patients, while using product revenue and collaboration income to fund development. The company markets and distributes its products through third parties rather than owning manufacturing or distribution assets. Akebia’s commercial story is closely tied to Vafseo, its approved HIF-PH inhibitor, and Auryxia, its established kidney-disease therapy that recently lost U.S. exclusivity and now faces generic competition. ## Products & services • Vafseo (vadadustat) for anemia due to CKD in dialysis patients • Auryxia for CKD-related complications and phosphate control • License, collaboration and supply revenue from partners • Clinical development of rare kidney disease programs • In-licensing and acquisition of kidney-focused assets - **Commercial kidney disease therapies** (95%) — Approved products sold to treat complications of chronic kidney disease, including anemia and related metabolic issues. - **Collaboration and license revenue** (5%) — Royalty, license fee, and supply revenue generated under partner agreements in Japan and other markets. - **Pipeline development programs** (0%) — Mid-stage and early-stage programs targeting rare kidney diseases and adjacent indications. - Vafseo (vadadustat) for anemia due to CKD in dialysis patients - Auryxia for CKD-related complications and phosphate control - License, collaboration and supply revenue from partners - Clinical development of rare kidney disease programs - In-licensing and acquisition of kidney-focused assets ## Customers Akebia sells primarily into the kidney-care ecosystem rather than directly to consumers. Its core buyers and influencers are dialysis organizations, nephrologists, specialty pharmacies, wholesalers, and healthcare providers that prescribe or distribute therapies for CKD complications. Patient adoption matters because both Vafseo and Auryxia depend on physician prescribing, payer access, and acceptance of the therapy’s safety, efficacy, and convenience versus alternatives. The company also relies on partners in certain markets for commercialization, which makes partner execution and market access important to revenue generation. - **Dialysis providers and dialysis organizations** (primary) — They purchase or influence use of therapies for patients receiving dialysis, especially Vafseo and Auryxia, because these patients have high unmet need and chronic treatment requirements. - **Nephrologists and other prescribers** (primary) — They decide whether to initiate treatment based on clinical profile, safety, labeling, and comparative convenience versus ESA or phosphate-binder alternatives. - **Specialty pharmacies and wholesalers** (secondary) — They handle distribution of commercial product supply and are essential to product availability and reimbursement flow. - **International commercial partners** (secondary) — Partners such as Medice, MTPC, JT, and Torii generate collaboration, royalty, and supply revenue through licensed commercialization arrangements. - **Clinical trial and research collaborators** (emerging) — Academic, clinical, and commercial collaborators support development of the pipeline and future label-expansion opportunities. - Dialysis organizations that buy Auryxia and Vafseo for CKD patients - Nephrologists who prescribe based on efficacy, safety, and convenience - Specialty pharmacies and wholesalers that distribute commercial supply - Patients with CKD-related anemia or phosphate-control needs - Commercial partners that license, market, or distribute products in ex-U.S. markets ## Geography Akebia is headquartered in the United States and its commercial base is centered on the U.S. kidney-disease market. The company’s manufacturing footprint is outsourced, with third-party CMOs producing clinical and commercial supply and third-party distributors handling product logistics. Outside the U.S., Akebia has collaboration and supply relationships with partners including Medice, MTPC, JT, and Torii, which provide a smaller but meaningful non-U.S. revenue stream. Geography matters because Vafseo’s approval and commercialization are country-specific, while Auryxia’s U.S. loss of exclusivity has increased competitive pressure in its largest market. - United States is the core commercial market for Vafseo and Auryxia - Non-U.S. revenue is supported by collaboration and supply partners - Commercial execution depends on country-specific marketing approvals - Manufacturing is outsourced to third-party CMOs rather than owned plants - Distribution is handled through wholesalers, specialty pharmacies, and logistics partners ## Strategy Akebia’s strategy is to expand its kidney-disease franchise by growing Vafseo, defending and monetizing Auryxia after loss of exclusivity, and using partner revenue to support R&D. The company is also trying to advance a pipeline of mid-stage rare kidney disease programs and earlier-stage assets that could broaden its addressable market beyond the current commercial products. Because it does not own manufacturing or distribution infrastructure, execution depends on third-party partners and disciplined supply-chain management. Financing and capital allocation remain strategic priorities, as the company continues to fund development while managing debt, royalties, and commercialization costs. - **Expand Vafseo commercialization** (short-term) — Vafseo is the company’s key growth product and the main driver of future kidney-franchise expansion. - **Monetize Auryxia after loss of exclusivity** (short-term) — Auryxia remains a revenue source, but generic competition makes retention and contract execution critical. - **Advance the kidney pipeline** (medium-term) — Pipeline success is needed to diversify beyond current commercial products and support long-term growth. - **Preserve financial flexibility** (short-term) — The company continues to rely on external capital and must balance R&D investment with debt and liquidity needs. - Grow Vafseo adoption in dialysis-related anemia - Manage Auryxia post-exclusivity and defend remaining demand - Use collaboration and royalty revenue to support pipeline investment - Advance rare kidney disease programs into later-stage development - Pursue in-licensing, acquisitions, and partnerships to broaden the portfolio - Maintain access to capital while servicing debt and funding operations ## Risks Akebia faces the classic risks of a small commercial-stage biopharma company: dependence on a limited number of products, heavy reliance on regulatory approvals, and ongoing need for capital. Auryxia’s U.S. loss of exclusivity creates a direct revenue and margin risk because generic entry can quickly compress pricing and volume. Vafseo’s growth depends on physician adoption, payer coverage, safety perceptions, and the ability to secure or expand marketing approvals in each country. The company also depends on third-party manufacturers and distributors, so supply disruptions, quality issues, or partner underperformance could interrupt sales. More broadly, biotech competition, clinical-development failure, patent disputes, and dilution from financing are material risks to both operations and shareholder value. - **Loss of exclusivity and generic competition for Auryxia** [high] — Once exclusivity ended, an authorized generic entered the U.S. market, which can pressure price, volume, and contract retention. - **Commercial adoption risk for Vafseo** [high] — Revenue depends on physician prescribing, patient acceptance, and payer coverage in a competitive anemia market. - **Regulatory and label-expansion risk** [high] — The company must maintain approvals and may need additional approvals for broader use or new indications. - **Third-party manufacturing and distribution dependence** [medium] — Akebia does not own manufacturing facilities and relies on CMOs and logistics partners for supply continuity. - **Capital and dilution risk** [high] — The company has a history of losses and may need additional financing to fund operations and development. - Auryxia generic competition after loss of exclusivity can reduce revenue and margins - Vafseo adoption risk depends on physician, patient, and payer acceptance - Regulatory risk remains high because approvals and label expansions are country-specific - Third-party CMO and distributor dependence can create supply and execution risk - Clinical development risk could delay or fail pipeline programs - Capital needs may force dilutive equity issuance or additional debt - Patent and intellectual property disputes could weaken product protection ## Accounting Akebia’s reported results are highly sensitive to product revenue reserves, royalty obligations, and the timing of commercialization milestones. Revenue from product sales is affected by rebates, returns, and reserves, which can materially change net revenue versus gross billings in a specialty-pharma model. The company also records collaboration, license, and supply revenue under partner agreements, so the timing of performance obligations and partner activity can create quarter-to-quarter variability. On the expense side, inventory reserves, idle-capacity charges, and write-offs can move cost of goods sold, while intangible asset amortization and fair-value changes in warrant liabilities can create large non-operating swings. Goodwill, right-of-use assets, and other long-lived assets also require judgment, so impairment assumptions matter for reported earnings and balance-sheet values. - **Product revenue reserves and rebates** — Can materially change reported product revenue and gross margin - **Collaboration and license revenue recognition** — Creates quarter-to-quarter variability in other revenue - **Inventory reserves and excess stock write-offs** — Affects cost of goods sold and operating margin - **Intangible asset amortization** — Reduces operating income and distorts comparability - **Fair value of warrant liability** — Can create non-cash earnings volatility - Net product revenue is reduced by rebates, returns, and reserves - Collaboration and license revenue depends on partner activity and contract terms - Inventory reserves and write-offs can affect cost of goods sold - Intangible asset amortization can materially affect reported gross margin - Fair value changes in warrant liabilities can create non-operating volatility - Goodwill and long-lived asset impairment judgments affect balance-sheet values --- *Last updated: 2026-08-11T04:46:19.797901+00:00*